TGTX Q3 2022 Earnings — TG Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TGTXTG Therapeutics, Inc.

$5B

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$94,000-95.4% YoY

Gross Profit

$92,00097.9% margin

Operating Income

-$35M-37194.7% margin

Net Income

-$36M-38104.3% margin

EPS (Diluted)

$-0.26

QoQ Revenue Growth

-84.2%

Cash Flow

Operating Cash Flow

-$34M

Free Cash Flow

-$34M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$218M

Total Liabilities

$117M

Stockholders' Equity

$100M

Cash & Equivalents

$110M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$94,000	$2M	-95.4%
Gross Profit	$92,000	$2M	-94.7%
Operating Income	-$35M	-$85M	+58.9%
Net Income	-$36M	-$86M	+58.2%

Revenue Segments

Product revenue, net

$56,00060%

License revenue

$38,00040%